RecruitingPhase 1Phase 2NCT03024008

Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II

A Multicenter Study to Evaluate the Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II


Sponsor

BonusBio Group Ltd

Enrollment

40 participants

Start Date

Jul 27, 2017

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this clinical study is to evaluate the safety and the efficacy of BonoFill-II as an autologous bone-regenerating graft in the reconstruction of deficient bone in two clinical indications: 1. Long and short bone extra-articular comminuted fracture 2. Long and short bones extra and intra articular defect /Gap or non-union, incapable of self-regeneration


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria2

  • Long and short bones extra articular comminuted fracture or
  • Long and short bones extra and intra articular defect/gap or non union, incapable of self-regeneration

Exclusion Criteria22

  • Age is under 18 or above 80
  • A simple fracture manageable by one definitive treatment
  • Pregnant or lactating women
  • Patients with active infection that is in question and needs osteogenic treatment.
  • More than 3 previous failed interventions at the surgical site
  • History of advanced congestive heart failure or active acute myocardial infarction (AMI), renal failure (estimated GFR of <30 ml/min/1.73 m2 at screening), or hepatic disease (hepatic insufficiency classified as Child-Pugh B or C)
  • Diabetic subjects (HbA1c > 8)
  • Subject treated currently with systemic steroids.
  • Subjects with known autoimmune diseases, such as Addison's disease, Celiac disease - sprue (gluten-sensitive enteropathy), Dermatomyositis, Graves disease, Hashimoto's thyroiditis, Multiple sclerosis, Myasthenia gravis, Pernicious anemia, Reactive arthritis, Rheumatoid arthritis, Sjogren syndrome, Systemic lupus erythematosus.
  • Subjects diagnosed with osteoporosis
  • Chronic severe PVD (Peripheral Vascular Disease) subjects
  • Post major vascular operation in the treated limb/s and above the surgical site (with or without Gore-Tex grafting)
  • Subjects that have a known scar healing problem (keloid formation).
  • Subjects treated with Bisphosphonate drugs
  • Oncology patient or subjects who received chemotherapy or radiotherapy treatment in the past 12 months
  • Immunocompromised condition from any reason, at screening
  • Subjects participating in another clinical trial 30 days prior to and during the study period.
  • Drug addicts and psychiatric patients patients incapable of giving consent.
  • Subjects with a known history of any significant medical disorder, which in the investigator's judgment contraindicates the subject's participation
  • Subjects with any known allergy for local/general anesthesia
  • Positive serology for either HIV, hepatitis B or hepatitis C
  • Abnormal clinically significant laboratory test and findings, as per the investigator's judgment

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALBonoFill-II

Surgery will be performed under local or general anesthetics according to the Investigator's and anesthesiologist discretion. A standard orthopedic approach will be made according to the fracture site.Then the transplantation of BonoFill-II into the fracture site and the fixation of the fracture by intramedullary nail or plate and screws or external fixator as required will be performed. internal fixation (plate and screws and intramedullary nails) will not be routinely removed. External fixators will be removed upon achievement of satisfactory bone union.


Locations(6)

Emek Medical Center

Afula, Israel

Barzilai Medical Center

Ashkelon, Israel

Hillel Yafe

Hadera, Israel

Carmel Medical Center

Haifa, Israel

Rambam Health Campus

Haifa, Israel

Meir Medical Center

Kfar Saba, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03024008


Related Trials